Key details
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Collaborators
Peking University Cancer Hospital & Institute
Enrollment target
~9 participants
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated December 2024